Younger adults with lung cancer more likely to have targetable genetic changes, study finds

Younger adults diagnosed with lung cancer are significantly more likely to possess genetic alterations that can be targeted with specific therapies, according to a comprehensive international study led by researchers at Sylvester Comprehensive Cancer Center. The findings, set to be presented at the 2026 World Conference on Lung Cancer, reveal that nearly 58% of younger patients exhibited guideline-recommended actionable alterations, compared to approximately 45% of patients aged 55 or older.

This suggests that age may play a crucial role in understanding tumor biology and selecting appropriate treatments. Older patients typically presented with KRAS-related changes and a higher tumor mutational burden, indicating a greater number of mutations overall. The study also uncovered age-related variations in immune markers, such as LAG3 and TIGIT, which could potentially serve as targets for future immunotherapy.

Researchers emphasize that age should be considered in conjunction with traditional biomarkers when evaluating treatment options for lung cancer patients. As precision medicine advances, it is essential to consider not only the specific mutations present but also how tumor biology evolves throughout a patient's lifetime. This research supports the broader use of comprehensive genomic profiling, particularly for younger adults diagnosed with non-small cell lung cancer, as it can aid doctors in identifying genetic drivers of the tumor that may respond to targeted therapies.